BEIJING: Chinese drug companies have been on a tear in the US stock market. Now, entrepreneurs and investors betting on the Asian country’s fledgling biotechnology industry see another reason for optimism.
The stock exchange in Hong Kong – home to the world’s fourth-largest equity market – is in the midst of weighing a proposal that would allow biotech companies to list even before they turn a profit.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
